Literature DB >> 26457456

Efficacy of High-Dose Baclofen for Alcohol Use Disorder and Comorbid Bulimia: A Case Report.

Sébastien Weibel1,2, Laurence Lalanne1,2, Myriam Riegert1, Gilles Bertschy1,2,3.   

Abstract

High-dose baclofen is a promising treatment for alcohol use disorder, with a specific action on craving. A more general action on craving in other addictive disorders has been suggested based on the hypothesis of a common neurobiological pathway in addictions. We report the case of a woman with both alcohol use disorder and bulimia nervosa. There was a positive response to high-dose baclofen on alcohol craving, but no response on food craving. The case illustrates that craving could be differentially responsive to anti-craving drugs.

Entities:  

Keywords:  addiction; alcohol; baclofen; bulimia; craving; drug

Mesh:

Substances:

Year:  2015        PMID: 26457456     DOI: 10.1080/15504263.2015.1104483

Source DB:  PubMed          Journal:  J Dual Diagn        ISSN: 1550-4271


  4 in total

Review 1.  From gene networks to drugs: systems pharmacology approaches for AUD.

Authors:  Laura B Ferguson; R Adron Harris; Roy Dayne Mayfield
Journal:  Psychopharmacology (Berl)       Date:  2018-03-01       Impact factor: 4.530

Review 2.  Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Francisco Romo-Nava
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

Review 3.  Baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders.

Authors:  Roberta Agabio; Lorenzo Leggio
Journal:  Front Psychiatry       Date:  2018-09-28       Impact factor: 4.157

4.  Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.

Authors:  Christophe Chaignot; Mahmoud Zureik; Grégoire Rey; Rosemary Dray-Spira; Joël Coste; Alain Weill
Journal:  Pharmacoepidemiol Drug Saf       Date:  2018-09-25       Impact factor: 2.890

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.